{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subdermal+Injection", "query": { "intervention": "Subdermal Injection" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Subdermal+Injection&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T08:08:02.010Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03660046", "title": "Contraceptive Hormones, Immunity, and Microbiome Evaluation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hormonal Contraception" ], "interventions": [ { "name": "Depot medroxyprogesterone acetate (DMPA)", "type": "DRUG" }, { "name": "Etonogestrel implant (Eng-Implant)", "type": "DRUG" }, { "name": "Levonorgestrel IUD (Lng-IUD)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "FEMALE", "summary": "Up to 45 Years · Female only" }, "enrollment_count": 155, "start_date": "2018-12-07", "completion_date": "2023-09-07", "has_results": false, "last_update_posted_date": "2024-10-29", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03660046" }, { "nct_id": "NCT01873170", "title": "Quantification of Immune Cells in Women Using Contraception (CHIC II)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV", "Immune Cells (Mucosal and Systemic)", "Contraception" ], "interventions": [ { "name": "levonorgestrel exposure", "type": "DRUG" }, { "name": "DMPA exposure", "type": "DRUG" }, { "name": "etonogestrel exposure", "type": "DRUG" }, { "name": "IUD insertion", "type": "DEVICE" }, { "name": "subdermal contraceptive implant insertion", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "34 Years", "sex": "FEMALE", "summary": "18 Years to 34 Years · Female only" }, "enrollment_count": 326, "start_date": "2013-08", "completion_date": "2020-10", "has_results": false, "last_update_posted_date": "2021-12-27", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01873170" }, { "nct_id": "NCT02112097", "title": "ASIS for Enbrel in Plaque Psoriasis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plaque Psoriasis." ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 12", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 24", "type": "DRUG" }, { "name": "Efficacy of Enbrel subcutaneously at Week 36", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 24", "type": "DRUG" }, { "name": "Efficacy of Enbrel subdermally at Week 36", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 12", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 24", "type": "DRUG" }, { "name": "PASI 75 n(%) subcutaneously at Week 36", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 12", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 24", "type": "DRUG" }, { "name": "PASI 75 n(%) subdermally at Week 36", "type": "DRUG" }, { "name": "Adverse Reactions of Enbrel subcutaneously", "type": "DRUG" }, { "name": "Adverse Reactions of Enbrel subdermally at Week 36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ASIS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02112097" }, { "nct_id": "NCT02074293", "title": "ASIS for Botox in Cervical Dystonia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cervical Dystonia Adults ,", "Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus." ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 6", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 12", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 18", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 24", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 30", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 6", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 18", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 24", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 30", "type": "DRUG" }, { "name": "Adverse Reactions of Botox intramuscularly", "type": "DRUG" }, { "name": "Adverse Reactions of Botox subdermally", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "li nguyen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074293" }, { "nct_id": "NCT02294565", "title": "VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "VST-1001", "type": "DRUG" }, { "name": "99mTc-labeled sulfur colloid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vestan, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 147, "start_date": "2014-06", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2015-07-27", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 2, "location_summary": "Houston, Texas • Salt Lake City, Utah", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294565" }, { "nct_id": "NCT02321527", "title": "Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Perflutren Protein-Type A Microspheres Injectable Suspension", "type": "DRUG" }, { "name": "Contrast-Enhanced Ultrasound (CEUS)", "type": "DEVICE" }, { "name": "Biopsy + Radioactive Seed Placement", "type": "PROCEDURE" }, { "name": "Phone Call", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "DEVICE", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2015-07", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02321527" }, { "nct_id": "NCT02123615", "title": "ASIS for GAMMAGARD in Primary Immunodeficiency", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Immunodeficiency" ], "interventions": [ { "name": "Gadolinium For abdomen", "type": "DRUG" }, { "name": "Gadolinium For lower back", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 12", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 24", "type": "DRUG" }, { "name": "Efficacy of Gammagard subcutaneously at Week 36", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 36", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Gammagard subdermally at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 12", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subcutaneously at Week 36", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 12", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 24", "type": "DRUG" }, { "name": "Adverse Reactions of Gammagard subdermally at Week 36", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ASIS Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02123615" }, { "nct_id": "NCT02074150", "title": "ASIS for Botox in Upper Limb Spasticity", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Upper Limb Spasticity Unilaterally in Adults With History of Stroke", "Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors." ], "interventions": [ { "name": "Gadolinium", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 6", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 12,", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 18", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 24", "type": "DRUG" }, { "name": "Efficacy of Botox intramuscularly at Week 30", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 6", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 12", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 18", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 24", "type": "DRUG" }, { "name": "Efficacy of Botox subdermally at Week 30", "type": "DRUG" }, { "name": "Adverse Reactions of Botox intramuscularly", "type": "DRUG" }, { "name": "Adverse Reactions of Botox subdermally", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "li nguyen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2016-01", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2015-06-24", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Westminster, California", "locations": [ { "city": "Westminster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074150" }, { "nct_id": "NCT02144259", "title": "The Impact of Contraception on Postpartum Weight Loss", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Weight" ], "interventions": [ { "name": "DMPA immediately postpartum", "type": "DRUG" }, { "name": "Implanon immediately postpartum", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 100, "start_date": "2011-04", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2017-02-17", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02144259" }, { "nct_id": "NCT01299116", "title": "Long-Acting Reversible Contraception", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Contraception" ], "interventions": [ { "name": "DMPA", "type": "DRUG" }, { "name": "oral contraceptives", "type": "DRUG" }, { "name": "Implanon®", "type": "DRUG" }, { "name": "ParaGard®", "type": "DRUG" }, { "name": "Mirena®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "FHI 360", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "29 Years", "sex": "FEMALE", "summary": "18 Years to 29 Years · Female only" }, "enrollment_count": 916, "start_date": "2011-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-09-14T08:08:02.010Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01299116" } ] }